Aim: To assess the systemic exposure to test compound in preclinical species after administration as support to toxicological studies.


Background information: Toxicokinetic evaluations help to relate plasma concentrations of test compound (or metabolites) to the observed toxicity and guide dosing recommendations for clinical trials.

The toxicokinetics assessment is done by determining test compound concentrations in plasma from toxicological studies. At preset times and day of administration, blood samples are collected from each animal. Bioanalysis is done by UPLC-MS/MS after previous sample treatment (solid phase extraction, protein precipitation) with/without validated method (GLP/non-GLP study).

Experimental design:

Dose, route, and samples: variable with study
Animal species: rodent, non-rodent
Dosage regime: single or multiple dosing
Analytical method: UPLC-MS/MS quantification in plasma using calibration curves. Bioanalytical method is validated previously when study is done following GLPs.

Delivered results:

Standard toxicokinetic parameters determined by non-comparmental analysis
Statistical analysis of toxicokinetic parameters

Dear colleagues, collaborators, and friends,

After more than 30 years of shared endeavours, in which we have grown personally and professionally, and with our emotions on the surface, we announce the closure of our company. We have travelled together through ups and downs, celebrated successes and overcome challenges as a team.

We extend our deepest gratitude to each of you for your dedication, passion, and commitment to a shared goal: discovering new treatments for the benefit and well-being of patients.

As we bid farewell, let’s cherish the memories we’ve created, the bonds we’ve formed, and the impact we’ve made together. Though our paths may diverge, the spirit of collaboration and camaraderie that defines our community will always endure.

We leave proud of the work accomplished and thank you for being an integral part of our journey, wishing you success in all your future challenges.

With heartfelt appreciation,

Welab’s team

We are proud to announce that Welab is partner of this new EU funded project.

In collaboration with 12 partners from 6 countries, Welab Barcelona is establishing the Antivirus Pandemic Preparedness EuropeAn pLatform (APPEAL), a European research initiative aimed at enhancing preparedness for future pandemics. This EU funded collaboration will establish a comprehensive program for the development of broad-spectrum antiviral drugs within a five year time frame ensuring drug affordability and accessibility to low income countries.
Link to the press release: https://lnkd.in/d-jmV2CS